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Abstract: Serum cortisol levels were examined in 94 patients with bronchial asthma in
relation to dose of glucocorticoids and age. 1. The level of serum cortisol was
significantly lower in group A patients, treated with glucocorticoids (prednisolone of
5 mg/day or more) for more than 2 years, (2.4 ± 1.2mcg/dQ) than in group S,
treated with glucocorticoids (prednisolone of 5 mg or less) for less than 2 years, (6.8
± 3.7mcg/dQ) (p<O.oo1) and in group C, treated without glucocorticoids, (12.6 ±
3.9mcg/dQ) (p<O.OO1). The serum cortisol level was also significantly lower in group
B than in group C (p<O.OO1). 2. The level of serum cortisol was significantly lower
in patients over the age of 70 compared to that in those aged between 0 and 39 years
(p<O.01) and those between 40 and 49 (p<0.05), and those between 50 and 59
(p<0.02). The level was also lower in patients between 60 and 69 compared to that in
those between 0 and 39, however, this was not significant.
These results demonstrate that the level of serum cortisol decreases by long-term
glucocorticoid regimen and with aging.
Key words: serum cortisol level, bronchial asthma, clinical asthma type, glucoco-
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Introduction
In the onset mechanism of asthma,
humoral factors such as histamine and
leukotrienes in the early stage of asthma
attacks 12), and cellular components such as
lymphocytes, neutrohils, eosinophils, and
basophils in the late stage J - 5) have been
shown to play important roles. Particularly
in recent years, attension has been focused on
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aIrway inflammation 6 - 8), since it IS closely
related to the severity of asthma 9). In many
patients with bronchial asthma, their attacks
can be controlled with the usual antiasthma
drugs, such as bronchodilators, expectorants,
antiallergic agents, and inhalant glucocor-
ticoids. However, there are some asthma
patients whose attacks cannot be controlled
with conventional antiasthma drugs, and who
often require longterm systemic glucocor-
ticoid therapylO-12). Although glucocorticoids
are effective in severe asthma attacks, the
many adverse side effects of these drugs,
such as the induction of hypertension, diabe-
tes mellitus, osteoporosis, and muscle weak-
ness, should be considered. Furthermore, the
suppression of adrenocortical glands by long-
term systemic glucocorticoid regimen, clini-
cally observed as reduced levels of serum
cortisol, IS important in the treatment of
asthma.
In the present study, serum cortisol levels
in patients with asthma were examined in
relation to dose of glucocorticoids used and
patient age.
Subjects and Methods
The subjects were 94 patients with asthma
(51 females and 43 males, mean age 53.3
years, range 16 -82 years). The subjects were
divided into three groups according to dose
of glucocorticoids used : patients who had
been treated with glucocorticoids for more
than 2 years and whose maintenance dose of
prednisolone of 5 mg / day or more (group
A), those treated with 5 mg / day of
prednisolone or less for less than 2 years
(group B), and those treated without
glucocorticoids (group C). The subjects were
further divided into 5 groups according to
their age: 0 ~39, 40-49, 50-59, 60-69, and
70 + years.
Asthma classification was made according
to clinical symptoms based on previously
reported criteria1H5). Type Ia. Simple broncho-
constriction: patients with symptoms such as
wheezing and dyspnea, which are elicited
mainly by bronchoconstriction. In this study,
this type was further divided into two sub-
types according to the amount of expectora-
tion ; type Ia - 1 (0 - 49mR / day) and type
la- 2 (50-99mP/day).
Type lb. Bronchoconstriction + hypersecre-
tion : patients with symptoms due to
hypersecretion (more than 100 mR / day of
expectoration), in addition to bronchoconstri-
ction.
Type II. Bronchiolar obstruction : patients
with symptoms elicited mainly by bronchiolar
obstruction.
Serum cortisol levels were measured by
radioimmunoassay (RIA) between 7 : 00 and
8 : 00 a.m. within a few days after the pa-
tients were admitted to our hospital.
The level of serum IgE was determined by
radioimmunosorbent test (RIST).
Results
Relation to dose of glucocorticoids used
Table 1 shows characteristics of patients
classified by dose of glucocorticoids/day.
The mean age was not different among three
groups. Mean serum IgE levels were lowest in
group A, patients treated with 5 mg of
prednisolone or more for 2 years or more,
however no significant difference was present
in serum IgE levels among three groups.
Figure 1 shows proportion of each clinical
type of asthma in the three asthma groups.
The proportion of type Ia - 1 asthma was
higher in group C, patients treated without
glucocorticoids. In contrast, the proportion of
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type II asthma higher in group A and group
B, patients treated with prednisolone of 5
mg or less for less than 2 years, compared to
that in group C.
In group B (6.8 ± 3.7mcg/ de) (p<O.OOl)
and than in group A (2.4 ± 1.2mcg/ de)
(p<O.OOl). The level was significantly higher
in group B compared to that in group A
(p<O.OOl) (Fig. 2).
Serum cortisol level was significantly
higher in group C (12.6 ± 3.9mcg/ de) than
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Fig. 2. Serum cortisol levels in each asthma
group classified by glucocorticoids used. A :
patients treated with prednisolone of 5
mg/day or more for more than 2 years, B
: patients treated with prednisolone of less
than 5 mg/day for less than 2 years, C :
patients without prednisolone. a, b, and c ;
p<O.OOl.
Relation to patient age
The serum cortisol level in patients of
group C (patients treated without glucocor-
ticoids) was significantly lower in patients
over the age of 70 years (9.5 ± 3.6mcg/dR)
compared to that in patients aged between
o and 39 years (15.5 ± 2.0mcg/ de )
(p<O.Ol), in those between 40 and 49 (15.6
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Table 1 . Characteristics of patients with
asthma, classified by dose of glucocorti-
coids perday
Asthma No of Age Serum IgE
group patients (years) (IU/ml)
A 37 54.4 299
( 18-3058)
B 25 53.5 590
( 18-2420)
C 32 57.4 437
(11-1397)
Fig. 1. Dose of glucocorticoids used and
clinical asthma types in patients with
asthma. Clinical asthma type: type Ia - 1
( 0 ), Ia - 2 (~), Ib ( !II ), and IT
( • ). A : patients treated with predniso-
lone of 5 mg/day or more for more than
2 years, B : patients treated with predni-
solone of less than 5 mg/day for less than
2 years, C : patients without prednisolone.
A; patients treated with prednisolone of 5 mg/day or
more for more than 2 years, B: patients treated with
prednisolone of less than 5 mg/day for less than 2
years, C: patients treated without prednisolone.
Asthma
group 0
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patients of group C (treated without
prednisolone), classified by age. a, p<O.Ol,
b ; p<0.05, c ; p<0.02.
The level of serum cortisol in patients of
group B (patients treated with prednisolone
of 5 mg or less for less than 2 years) was
lowest in patients aged between 50 and 59
years (5.8 ± 3.4mcg/ dR), however, there
were no significant differences among five
age groups (Fig. 4).
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Fig. 4. Serum cortisol levels
patients of group B (treated
solone of less than 5 mg/day
2 years), classified by age.
In group A patients (treated with predni-
solone of 5 mg or more for more than 2
years), the serum cortisol level was in gen-
eral low (range 1.8 - 2.8mcg/ dR), although
no significant differences were present among
five age groups (Fig. 5).
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気管支鳴息患者の血清コーチゾール値について.
副腎皮質ホルモン投与および年齢との関連
保崎泰弘,御船尚志,光延文裕,梶本和宏,
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気管支瑞息94例を対象に,副腎皮質ホルモン投
与および年齢との関連のもとに,血清コーチゾー
ル値の変動を観察した｡まず副腎皮質ホルモンの
投与量および投与期間により以下の3群に分けて
検討した｡グループA:副腎皮質ホルモン,プレ
ドニソロンに換算して1日57ng以上を2年間以上
にわたり使用している症例,グループB:プレド
ニソロン1日5mg以下で2年間以内の使用症例,
グループC:副腎皮質ホルモンを全く使用してい
ない症例｡その結果,グループAの血清コーチゾ-
ル値 (2.4±1.2mcg/dP)は,グループB (6.8
±3.7mcg/dP)(p0.01)やC (12.6± 3.9
mcg/dP)(p0.001)に比べ有意に低い値であっ
た｡2､グループCでは,70才以上の症例の血清
コーチゾ-ル値は,0-39才の症例 (p0.Ol),
40-49才の症例 (p0.05),そして,50-59才の
症例 (p0.02)に比べ有意に低い値であった｡
これらの結果は,血清コーチゾール値は,副腎
皮質ホルモンの投与量や投与期間以外にも､加齢
による影響を受ける可能性を示唆している｡
キーワード:血清コーチゾ-ル,気管支鴨息,臨
床病型,副腎皮質ホルモン,加齢
